Abstract
The alpha-herpesviruses varicella zoster virus (VZV) and herpes simplex virus (HSV) share common features including lifelong persistence in sensory ganglia and the risk of recurrences. For both HSV and VZV, standard-of-care (SoC) is based on nucleoside analogs (NAs), which require specific activation in infected cells. These existing drugs exhibit substantial limitations, warranting the development of new and more effective drugs.
© 2017 American Society for Clinical Pharmacology and Therapeutics.
MeSH terms
-
Antiviral Agents* / classification
-
Antiviral Agents* / pharmacology
-
DNA Helicases / antagonists & inhibitors
-
DNA Primase / antagonists & inhibitors
-
Herpes Simplex / drug therapy*
-
Herpes Simplex / virology
-
Herpes Zoster / drug therapy*
-
Herpes Zoster / virology
-
Herpesvirus 3, Human* / drug effects
-
Herpesvirus 3, Human* / physiology
-
Humans
-
Medication Therapy Management / trends
-
Nucleosides / pharmacology
-
Simplexvirus* / drug effects
-
Simplexvirus* / physiology
-
Viral Proteins / antagonists & inhibitors
-
Virus Replication / drug effects
Substances
-
Antiviral Agents
-
Nucleosides
-
Viral Proteins
-
DNA Primase
-
helicase-primase, Human herpesvirus 1
-
DNA Helicases